Hereditary neuroblastoma

Hereditary neuroblastoma is a malignant tumor that originates from primitive neuroblasts, which are the cells responsible for the development of the sympathetic nervous system. Neuroblastoma most often occurs in young children, primarily under the age of five, and can develop in various parts of the body, although it is most common in the adrenal glands, neck, and spine. This type of tumor is characterized by aggressive behavior and a high risk of metastasis, making timely diagnosis and treatment especially important.

History of the disease and interesting historical facts

Neuroblastoma was first described in 1910 and remained a relatively rare disease with only a few known cases until the mid-20th century. In 1944, one of the first surgical interventions to remove the tumor was successfully performed, which became the basis for further research into the treatment of this disease. In 1971, the FDA first approved the use of chemotherapy to treat neuroblastoma, which was a significant breakthrough in oncology. Interestingly, the tumor got its name from the Latin term “neuroblastus,” meaning “underdeveloped nerve cell.” Scientists are still working to understand the molecular mechanisms of neuroblastoma development, which opens up new horizons for the development of targeted therapies.

Epidemiology

Neuroblastoma accounts for approximately 6-10% of all childhood cancer cases and is the most common solid tumor in children. According to the American Cancer Society, approximately 650 new cases are diagnosed in the United States each year. Children aged 1 to 4 years are most susceptible to the disease, with boys being affected more often than girls, with a ratio of 1.5:1. Geographical differences are also noted: high incidence rates are recorded in Japan and Western Europe, while significantly fewer cases are observed in Asian and African countries.

Genetic predisposition to this disease

Research shows that genetic predisposition to neuroblastoma may be linked to mutations in certain genes. The most significant of these include NMYC, which is associated with aggressive forms of the tumor, and ALK, mutations in which are associated with the development of the disease in some children. Research shows that approximately 1 in 10 cases of the disease may be linked to genetic factors. Patients with prenatal tumor syndromes, such as Li-Fraumeni syndrome, also have a significantly increased risk of developing neuroblastoma.

Risk factors for the development of this disease

Risk factors for the development of neuroblastoma can be divided into two categories: physical and chemical. Physical factors include:

• Positive family history of the disease indicating a hereditary predisposition.
• Gender of the child: Boys are at greater risk.
• Age: Most cases occur in children under 5 years of age.

Chemical risk factors include:

• Exposure to certain chemicals, such as pesticides and industrial solvents.
• Aggressive external factors associated with environmental pollution.

Research is also underway on the role of viruses such as Epstein-Barr virus in the pathogenesis of neuroblastoma, but these data require further study.

Diagnosis of this disease

Various research methods are used to diagnose neuroblastoma. The main symptoms of the disease include:

• Enlargement of the abdomen (due to a tumor in the adrenal glands).
• Bone pain and/or behavioral changes.
• Swelling and bruising that occurs without apparent cause.

Laboratory tests include tests for specific markers such as urinary metanephrines and vanillyl manganese acid. Radiological tests may include ultrasound, CT, and MRI to visualize the tumor and metastases. Other diagnostic tests may include biopsy of the affected tissue. It is important to differentiate other tumors such as nephroblastoma or osteosarcoma to rule out other possible pathologies.

Treatment

Treatment of neuroblastoma requires a multidisciplinary approach and includes several methods:

• Surgical intervention aimed at tumor resection.
• Chemotherapy, which may include combinations of different drugs, such as cyclophosphamide and dexorubicin.
• Radiation therapy used to shrink a tumor or kill any remaining cancer cells after surgery.
• Immunotherapy, which is aimed at enhancing the immune response against the tumor.

Each case requires an individual assessment to select the best treatment strategy.

List of medications used to treat this disease

The main pharmacological drugs used in the treatment of neuroblastoma include:

• Cyclophosphamide
• Dexorubicin
• Vincristine
• Ippusin
• Topotecan

When using these drugs, it is important to consider potential side effects and the need for patient monitoring.

Disease monitoring

To monitor the patient's condition after treatment for neuroblastoma, regular monitoring stages are carried out:

• Regular check-ups, including physical examination and imaging tests.
• Determination of marker levels in the blood and urine at the junction of therapy and to identify relapses.
• Evaluation of possible complications from the treatment, such as secondary diseases.

The prognosis for patients depends on the stage of the disease, the presence of metastases and age at diagnosis, but overall the survival rate of patients with early stage disease is superior to 90%.

Age-related features of the disease

Age groups play an important role in the clinical course of neuroblastoma. Younger children tend to have more aggressive forms of the disease, while older children may progress more slowly. It is important to consider that the younger the child, the more unfavorable the prognosis. This is due to the fact that infants often have a higher degree of metastasis and a severe course of the disease.

Questions and Answers

• What is neuroblastoma? It is a malignant tumor originating from primitive neuroblasts, often occurring in young children.
• What symptoms may indicate neuroblastoma? The main symptoms include an enlarged abdomen, bone pain, and changes in the child's behavior.
• How is neuroblastoma diagnosed? Diagnosis includes laboratory tests, radiological examinations and biopsy to confirm the diagnosis.
• What is the treatment for neuroblastoma? Treatment may include surgery, chemotherapy, radiation therapy, and immunotherapy.
• What is the prognosis for children with neuroblastoma? The prognosis depends on the stage of the disease, the presence of metastases and the patient's age, but survival with early treatment can reach 90%.

Advice from Dr. Oleg Korzhikov

When diagnosing neuroblastoma, it is important to immediately contact specialized specialists for comprehensive treatment. I recommend that parents be attentive to any changes in the child's health, do not ignore complaints and undergo examinations in a timely manner. Having a positive family history requires more careful monitoring. It is also important to remember that the resilience and support of the family plays a big role in the treatment process, since the emotional state of the child and his environment directly affects the results of therapy.